Glucolabs Healthcare Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 21-12-2024
- Paid Up Capital ₹ 0.10 M
as on 21-12-2024
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
About Glucolabs Healthcare
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Babita Saxena, Deepak Sharma, and Orikolodatte Nair serve as directors at the Company.
- CIN/LLPIN
U24231MP2021PTC054737
- Company No.
054737
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Feb 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Glucolabs Healthcare Private Limited offer?
Glucolabs Healthcare Private Limited offers a wide range of products and services, including Allopathic Cough Syrup, Dextromethorphan Cough Syrup, Cough Syrup, Ayurvedic Digestive Medicine, Digestive Enzyme Syrup.
Who are the key members and board of directors at Glucolabs Healthcare?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Babita Saxena  | Director | 03-Feb-2021 | Current |
| Deepak Sharma | Additional Director | 23-May-2022 | Current |
| Orikolodatte Nair | Additional Director | 23-May-2022 | Current |
Financial Performance of Glucolabs Healthcare.
Glucolabs Healthcare Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Glucolabs Healthcare?
Unlock access to Glucolabs Healthcare's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Glucolabs Healthcare?
Glucolabs Healthcare has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glucolabs Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glucolabs Healthcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
